Seven Eight Capital, LP Crinetics Pharmaceuticals, Inc. Transaction History

Seven Eight Capital, LP

  • $1.05 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
SELL
$42.12 - $51.91 $520,603 - $641,607
-12,360 Reduced 60.26%
8,150 $365,000
Q1 2024

May 13, 2024
SELL
$34.76 - $46.81 $500,613 - $674,157
-14,402 Reduced 41.25%
20,510 $960,000
Q4 2023

Feb 13, 2024
BUY
$25.62 - $37.07 $894,445 - $1.29 Million
34,912 New
34,912 $1.24 Million

Others Institutions Holding CRNX

# of Institutions
241
Shares Held
79.6M
Call Options Held
23.3K
Put Options Held
44.3K
View Full List

About Crinetics Pharmaceuticals, Inc.

CRNX Quotes by TradingView
  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.94B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Seven Eight Capital, LP Portfolio

Follow Seven Eight Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Seven Eight Capital, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email